Inspection classificationInspection ended April 24, 2026
FDA inspection of Jiangsu Hansoh Pharmaceutical Group Co., Ltd: OAI
Official action indicated
FDA classified an inspection of Jiangsu Hansoh Pharmaceutical Group Co., Ltd in Lianyungang, China as OAI (official action indicated). The inspection ended on April 24, 2026. Product type: Drugs.
On the record
- Establishment
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd
- Location
- Lianyungang, China
- Classification
- OAI · Official action indicated
- Inspection ended
- 2026-04-24
- Product type
- Drugs
- Fiscal year
- FY2026
- FDA establishment identifier (FEI)
- 3008316144
- Source
- FDA Data Dashboard ↗
The full record
An account shows the project areas inspected and whether citations were posted.
What an inspection classification is
After an inspection FDA classifies the outcome. NAI (no action indicated): no objectionable conditions were found, or none that justify further action. VAI (voluntary action indicated): objectionable conditions were found, but the agency is not prepared to take or recommend regulatory action. OAI (official action indicated): regulatory or administrative action is recommended.
More
Watch Jiangsu Hansoh Pharmaceutical Group Co., Ltd
A free account shows the last 7 days of every FDA, SEC and ClinicalTrials.gov source. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA Data Dashboard; FDA posts a classification after its review, which can be months after the inspection ended. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.